Eye on Pharma: Eylea Biosimilar Suspension; New FDA Labeling

Samsung Bioepis suspends development for its biosimilar referencing Eylea (aflibercept); the FDA updates its labeling recommendations for interchangeable biosimilars; Alvotech receives a Form 483 after the FDA reinspected its Iceland-based manufacturing facility.

Related Keywords

Iceland , Reykjavik , C10 , South Korea , Korea , Samsung Bioepi Eylea , Samsung Bioepi , Stantond Alvotech , Sarah Yim , Samsung Bioepis , Samsung Bioepis Suspends Aflibercept Development , Bioprocess International , Korean Ministry Of Food , Korean Ministry , Drug Safety , Korea Biomedical , Pharmaceutical Affairs , Biosimilarity Statement , New Drug Office , Therapeutic Biologics , Reinspection Results , Cosmetic Act , Alvotech , Eylea , Aflibercept , Usfda Inspection , Fda Labeling , Fda Guidance , Avt04 , Avt06 , Form 483 ,